|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Medicine, Faculty of Health
Science, McMaster University, Hamilton, ON, Canada.
Recent studies investigating thrombotic thrombocytopenic purpura
(TTP) have implicated abnormal plasma von Willebrand factor (vWF)-cleaving metalloprotease activity in this disorder. It has been
proposed that a metalloprotease cleaves unusually large (UL) multimers
of vWF, which enter the circulation from the endothelium. Abnormal
metalloprotease activity could result in ULvWF, which could participate
in TTP. However, the diagnostic specificity of abnormalities in the
plasma metalloprotease activity has not been established. A prospective
study of vWF protease activity was performed using samples from 20 healthy controls, 20 patients with acute TTP, 20 patients with immune
idiopathic thrombocytopenic purpura (ITP), 10 patients with
disseminated intravascular thrombocytopenia (DIC), 10 patients with
systemic lupus erythematosus (SLE,) and 5 thrombocytopenic patients
with leukemia. Studies were performed blinded to the diagnosis. Samples
from hospitalized patients with normal platelet counts were also
tested. The vWF digests and multimer analysis were done using
previously described methods. Six laboratory personnel independently
scored each of the multimer gels. Reduced protease activity was
observed in 9 of 20 patients with TTP. Reduced activity was also
observed in 6 of 20 patients with ITP, 6 of 10 patients with DIC, 5 of
10 patients with SLE, 1 of 5 patients with leukemia, 2 of 20 healthy
controls, and 3 of 25 hospitalized patients. This study indicates that
abnormalities of vWF protease activity are not restricted to patients
with the diagnosis of TTP.
(Blood. 2001;98:1842-1846) The factor known as von Willebrand factor (vWF) is
a multimeric protein important for platelet adhesion. Physiologically, vWF is released from endothelial cells as unusually large (UL) multimers.1-4 Plasma vWF multimers are smaller, a finding
that suggests that released ULvWF is cleaved by a combination of
reductase and metalloprotease enzymes after it enters the
plasma.3-6
Thrombotic thrombocytopenic purpura (TTP) is a rare disorder
characterized by thrombocytopenia and schistocytic hemolytic anemia.
TTP is often associated with fever and renal and neurologic dysfunction. Pathologically, individuals with TTP have evidence of
intravascular, platelet-rich microthrombi that contain vWF. This has
led many to postulate that abnormally reactive vWF contributes to the
development of platelet-vWF-rich thrombi and tissue ischemia present
in TTP.7-20
Many patients with TTP have abnormalities of plasma vWF during their
acute illness.7-20 Recently, normal plasma was found to
contain a metalloprotease activity that converts ULvWF multimers to the
smaller forms in vitro. Several investigators subsequently reported
that many patients with TTP have abnormally reduced vWF protease
activity in their plasma.7,8,10,14,16,17,19,20 They
implicated antibodies that inhibit the vWF metalloprotease in patients
as the cause of sporadic but not familial TTP. These data have led to
the hypothesis that patients with acute, sporadic TTP have
antibody-mediated inhibition of the plasma metalloprotease, whereas
patients with familial TTP may have a congenital defect of this
enzyme.7,8,10,14,16,17
Although there are conflicting reports about the frequency of abnormal
ULvWF multimer profiles in acute TTP and during remission, there has
been general agreement that abnormalities of vWF are often observed in
TTP.6-20 However, the sensitivity and specificity of the
vWF metalloprotease assay has not been reported. This led us to
prospectively examine the levels of plasma vWF-cleaving protease
activity in patients with various thrombocytopenic disorders. Our
results indicate that abnormalities in vWF protease activity occur in a
significant proportion of patients with TTP. However, we observed
identical decreases in vWF protease activity in association with other
thrombocytopenic disorders and occasionally in nonthrombocytopenic controls.
Materials
Methods
Study design.
A total of 95 samples from various patient groups were collected and
coded to blind personnel to the patients' identities and diagnoses.
Assays for vWF protease activity and antigen levels were performed. To
rank the vWF protease activity, each multimer gel was analyzed
independently by 6 laboratory personnel. Any disagreement was resolved
by consensus prior to unblinding.
Patient and control samples.
This study was allowed by the university and hospital Ethics Review
Committee, and all samples were drawn in compliance with ethics guidelines.
 70°C until testing. Twelve patients had plasma samples (3.8%
sodium citrate) drawn at the same time, and for these patients the
plasma and sera were tested in parallel for vWF protease activity. To
evaluate intraassay variability, 7 samples were submitted in duplicate
with unique identifiers for each aliquot. Following unblinding, native
vWF multimer analysis was done on samples with decreased vWF protease
activity, including samples from 4 TTP patients, 2 ITP patients, 1 DIC
patient, 2 SLE patients, and 5 control samples.
Purification of target vWF.
The vWF was purified according to previously described
methods.5 Human cryoprecipitate, a gift of the Canadian
Blood Services, Hamilton, ON, was gel-filtered using a Sepharose CL-2B
column (Pharmacia, Uppsala, Sweden), equilibrated, and eluted using
0.13 M NaCl/0.01 M citrate/0.01 M Tris-HCl, pH 7.4. The vWF content of
eluted fractions was analyzed by reduced 5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as well as
SDS-multimer gels containing 1.25% agarose (Seakem LGT, FMC Bioproducts, Rockland, ME) and 1% acrylamide (Bio-Rad Laboratories, Richmond, CA).1 The proteins were transblotted onto
nitrocellulose (Pharmacia) before visualizing the vWF with
peroxidase-conjugated rabbit antihuman vWF (Dako, Denmark) and
chemiluminescent techniques (ECL, Amersham Pharmacia Biotech, England).
The fractions containing the largest multimers of vWF were analyzed
using SDS-PAGE and stained with Coomassie blue to confirm the absence
of other contaminating proteins. These fractions were then tested in
the vWF protease assay to confirm that there was no contaminating vWF
protease activity. The purified fractions were pooled, adjusted to a
concentration of 3 U/mL, aliquotted, and frozen at Protease assay for vWF. The vWF protease assay was performed using previously described methods.5,6,14 Test serum was diluted 1:3 in 0.15 M NaCL/10 mM Tris buffer, pH 7.4, and 100 µL was mixed with BaCl2 (10 mM) and serine protease inhibitors (1 mM Pefabloc, Boehringer Mannheim). Following a 5-minute incubation at 37°C, 50 µL purified protease-free vWF substrate (3 U/mL vWF antigen) was added.14 The substrate/test sample mixture was centered on a hydrophilic membrane (2 mm, VSWP, Millipore, Bedford, MA) and then dialyzed against 1.5 M urea/5 mM Tris hydrochloride, pH 8.0. Following a 24-hour incubation at 37°C, the digests were terminated by the addition of 10 mM ethylenediaminetetraacetic acid (EDTA). In addition, 3 samples from healthy controls and 3 TTP patients were tested using different dialysis buffers (1.0, 1.5, and 2.0 M urea/5 mM Tris, pH 8.0) to determine whether this altered the amount of protease activity detected. When varying concentrations of urea were tested, 1.0 and 1.5 M gave reproducible and comparable results, whereas 2.0 M urea decreased the proteolytic activity detected for all samples. Consequently, all results reported in this study were based on determinations using 1.5 M urea and 5 mM Tris, pH 8.0, as described by Furlan et al.5 The vWF multimers in the digests were analyzed using SDS-multimer gels containing 1.25% agarose and 1% acrylamide.1 Following electrophoresis (18 hours at 30 V), the proteins were transblotted onto nitrocellulose membranes and incubated with peroxidase-conjugated rabbit antihuman vWF antibodies. The vWF multimer patterns were developed using chemiluminescent techniques as described. Internal standards, on each gel, included target vWF, vWF digested by normal pooled serum, and vWF incubated with normal pooled serum containing 10 mM EDTA to block the metalloprotease activity. To ensure consistency in ranking, the degree of proteolysis of each sample was related to the migration of the target vWF run on the same gel. The total length of the target vWF multimer migration was divided into quadrants, and each quadrant was assigned a score from 4+ (only small vWF multimers remained) to 1+ (the complete array of vWF multimers remained intact). The score of vWF proteolysis of each sample was determined by matching its height of the vWF multimer migration to the corresponding quandrant established using the target vWF lane. Because the assay measured the ability of the test sample to proteolyze the target vWF, normal activity corresponded to the proteolysis of the large vWF multimers and scores of 3+ or 4+. Samples deficient in protease activity left large multimers intact and were ranked as 1+ or 2+ (Figure 1).
Statistical analysis. Statistical analysis was done using Minitab (Minitab Release 13.1, Minitab, State College, PA) computer program.
Validation of techniques There was good consensus between each of the individual evaluators and complete agreement in distinguishing normal versus decreased vWF proteolysis. The agreement between scorers was strong (r > 0.9, Pearson correlation coefficient test). The 7 duplicate samples tested had reproducible levels of vWF proteolysis. As noted by other investigators, the 12 paired plasma and serum samples produced identical patterns of vWF proteolytic activity.5Test results The normal pool run on each gel consistently scored as having 4+ protease activity. When EDTA was added prior to incubation, the protease activity was reduced, resulting in scores of 1+. Nine (45%) of the 20 TTP samples had reduced protease activity scores in all assays. Seven of the TTP patients with reduced protease reactivity had acute TTP, whereas the other 2 were from unrelated patients with familial TTP. The 2 familial TTP patients had the most reduced activity of all the patient and control samples tested. Both of these patients have had lifelong TTP, initially responding to plasma infusion but now requiring regular plasmapheresis. Of the other 7 TTP patients with reduced protease activity, 2 had relapsing TTP and ultimately recovered; 3 achieved complete remissions following an acute, single TTP episode; and 2 died during their acute TTP. However, 11 other patients with acute TTP had normal vWF proteolysis and were indistinguishable from healthy controls and the normal pool (Figure 1). This group included 2 patients with pregnancy-related TTP who achieved complete remission; 2 patients with relapsing TTP; 4 TTP patients who achieved complete remissions following an acute, single TTP episode; and 3 TTP patients who died during their acute TTP. Of the 3 TTP patients tested before and after plasmapheresis, 2 patients had normal protease activity at both time points and the other patient had decreased proteolysis (2+) on admission and normal protease activity postplasmapheresis (3+).Many patients with thrombocytopenic disorders other than TTP were noted
to have reduced plasma vWF protease activity and were scored
identically to the TTP patient samples. The proportion of patients with
reduced vWF protease activity in each of the diagnostic groups was 6 of
20 ITP, 6 of 10 DIC, 5 of 10 SLE, and 1 of 5 leukemic patients (Figure
2). Several of the control samples also
had decreased vWF protease activity (3 of 25 hospital controls and 2 of
20 healthy controls) (Figure 2).
The in vitro measurement of decreased protease activity did not correlate with an in vivo abnormal pattern of native plasma vWF. The native vWF multimers from the 2 healthy controls with decreased protease activity, 3 hospital controls, as well as samples from patients with thrombocytopenic disorders (4 TTP, 2 ITP, 1 DIC, 2 SLE) were analyzed, and there was no evidence of increased ULvWF multimers associated with their decreased plasma vWF cleaving protease activity. Three of the 4 acute TTP patient samples had reduced plasma high-molecular-weight vWF multimers, which have been previously described in episodes of acute TTP.9,12,18 Relationship of vWF protease activity and platelet count and vWF antigen levels When vWF protease activity scores were compared with subject platelet counts, the most marked decreases in vWF proteolytic activity (1+) were noted in individuals with severe thrombocytopenia (P < .001, nonpaired Student t test). Also, the most marked decreases in vWF protease activity were seen in individuals with higher vWF antigen levels (P < .001, nonpaired Student t test) (Figure 3).
TTP is an uncommon but important clinical disorder. Without treatment the illness is usually fatal; however, plasma exchange with or without corticosteroids results in the survival of approximately 75% of patients with acute TTP. The illness is also important because it is mediated by the formation of intravascular platelet thrombi and a better understanding of the pathogenesis of this disorder could contribute to the understanding of other platelet-mediated thrombotic conditions. Finally, further defining TTP could lead to more effective and targeted therapies because the mainstay of therapy, plasma exchange, is an empiric treatment.12,21 A number of hypotheses have been put forward to explain the platelet thrombi that characterize TTP. These include an abnormal apoptotic factor,22,23 a variety of platelet aggregating factors,24-27 and abnormalities of vWF.7-20 Our group has postulated that a platelet aggregating factor such as calpain, associated with platelet-derived microparticles, could participate in the disorder.11,25,28 Recently, other investigators have focused on factors that influence the cleaving of plasma vWF.7-10,14,16,17,19,20 Almost 20 years ago, Moake and associates noted abnormalities in vWF in patients with acute or convalescent familial TTP.13 Similar observations have been made by some but not all investigators.9,12,18,20 It is now agreed that many patients with TTP will have abnormalities of vWF, although the sensitivity and specificity of this observation is variable. Most recently, several groups of investigators have reported abnormally reduced cleavage of vWF by a plasma protease in patients with TTP.7-10,13,14,16,17,19,20 This is an attractive hypotheses because the abnormality could explain the abnormal vWF seen in the plasma of many patients with TTP. In this report, we describe a study designed to evaluate the sensitivity and specificity of the finding of abnormal vWF protease activity in patients with TTP. The test samples were collected from a number of patients and controls in whom the cause of the thrombocytopenia was well defined. But these test samples were then coded and all further investigations performed in a blinded fashion. Our study was designed to minimize problems often associated with the performance of complex laboratory assays in patients with uncommon disorders. Each step was controlled and validated. As a first step, we prepared a consistent protease-free target sample of vWF that was used for all assay determinations. Second, we tested varying dilutions of urea to ensure optimal protease activity. We compared duplicate plasma and serum samples and, in agreement with others, found that identical results were obtained. We included a normal pool with and without EDTA on each gel to ensure consistency in ranking vWF protease activity. The samples were coded, and the degree of proteolysis was scored independently by 6 different laboratory personnel familiar with vWF gel analysis. The technique we used to measure protease activity gave
consistent and reproducible results, and there was excellent agreement among all observers. Additionally, the 7 blinded duplicate samples gave
identical results. Consistent with the results of other investigators, we found that a number of our patients with acute TTP had detectable abnormalities of protease activity. However, because only 9 of the 20 TTP patient samples had reduced protease activity, the percentage that
we found with abnormalities (45%) was lower than others have reported.
Consistently, we observed that 2 unrelated patients with familial TTP
had the most markedly reduced level of vWF protease activity. However,
for the patients with acute TTP there was no relationship between
protease activity and disease severity. Indeed, both groups of TTP
patients Taken together, our result suggests that abnormalities of vWF protease are seen in patients with TTP, but the observation has only moderate sensitivity (0.45) and a low specificity (0.30). Our studies indicate that within each of the control groups there is a spectrum of vWF protease activity. Given the study design (blinded and coded, with independent observers using a standard scoring system before breaking the code), it is unlikely that observer bias could explain our results. Similarly, differences in the laboratory technique are an unlikely explanation because we followed the protocols (including defined urea concentrations) described by other investigators.5,14 Although other assays are available to measure abnormal vWF, the initial proteolysis of target vWF remains the same.7,19,20 Because the protease has not been isolated, measurements of abnormalities of the protease activity depend on indirect measurements. Collagen binding assays and assays that use monoclonal anti-vWF antibodies are less time-consuming and are able to detect abnormal vWF structures.19,20 The benefit of using vWF multimer analysis as an end point to the metalloprotease activity is that the technology is a standard method of assessing vWF multimers in routine laboratories and can be easily understood and interpreted. By including internal standards on each multimer run, standardization of scoring was obtained. The clinical significance of abnormalities of vWF protease activity remains uncertain. We observed a correlation between our results and the degree of thrombocytopenia as well as the relative concentration of vWF antigen level (Figure 3). However, it is important to note that a selection bias in our sample population could explain these observations. For example, our study focused on thrombocytopenic patients with a variety of disorders. Hence, this apparent association may be collateral rather than causal. The studies described in this report indicate that abnormalities of vWF protease activity as measured in a standard assay are not correlated with the presence or absence of TTP.
Submitted February 12, 2001; accepted May 18, 2001.
Supported by grants from the Medical Research Council of Canada and the Heart and Stroke Foundation of Ontario.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: J. G. Kelton, Canada Research Chair in Transfusion Medicine, HSC 3W10, McMaster University Medical Centre, 1200 Main St W, Hamilton, ON, Canada, L8N3Z5.
1.
Ruggeri ZM, Zimmerman TS.
The complex multimeric composition of factor VIII/von Willebrand factor.
Blood.
1981;57:1140-1143
2.
Tsai H-M, Nagel RL, Hatcher VB, Sussman II.
Multimeric composition of endothelial cell-derived von Willebrand factor.
Blood.
1989;73:2074-2076
3.
Dent JA, Berowitz SD, Ware J, Kasper CK, Ruggeri ZM.
Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor.
Proc Natl Acad Sci U S A.
1990;87:6306-6310 4. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand Factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78:1456-1461.
5.
Furlan M, Robles R, Lammle B.
Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.
Blood.
1996;87:4223-4234
6.
Tsai H-M.
Physiological cleavage of von Willebrand factor by a plasma protease is dependent on its confirmation and requires calcium ion.
Blood.
1996;87:4235-4244
7.
Tsai HM, Lian ECY.
Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
N Engl J Med.
1998;339:1585-1594
8.
Furlan M, Robles R, Galbusera M, et al.
Von Willebrand factor-cleaving protease in thrombotic thrombocytopenia and the hemolytic-uremic syndrome.
N Engl J Med.
1998;339:1578-1584
9.
Mannucci PM, Lombardi R, Lattuada A, et al.
Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura.
Blood.
1989;74:978-983 10. Moake JL. von Willebrand factor in the pathophysiology of thrombotic thrombocytopenic purpura. Clin Lab Sci. 1998;11:362-372[Medline] [Order article via Infotrieve]. 11. Moore JC, Murphy WG, Kelton JG. Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura. Br J Haematol. 1990;74:457-464[Medline] [Order article via Infotrieve]. 12. Rock GA. Management of thrombotic thrombocytopenic purpura. Br J Haematol. 2000;109:496-507[CrossRef][Medline] [Order article via Infotrieve]. 13. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307:1432-1435[Medline] [Order article via Infotrieve].
14.
Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B.
Deficient activity of von Willebrand factor-cleaving activity in chronic relapsing thrombotic thrombocytopenic purpura.
Blood.
1997;89:3097-3103 15. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with specific reference to factor VIII related antigen. Thromb Res. 1985;38:469-479[CrossRef][Medline] [Order article via Infotrieve]. 16. Tsai H-M, Lian EC-Y. Inhibitors to vWF-cleaving metalloproteinase in thrombotic thrombocytopenic purpura [abstract]. Blood. 1997;90(suppl 1):2620. 17. Krause M, Furlan M, Ehrenforth S. Relevance of the von Willebrand factor cleaving protease in the diagnosis and clinical course in patients with thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS) [abstract]. Blood. 1997;90(suppl 1):404. 18. Murphy WG, Moore JC, Barr RD, Pai MKR, Kelton JG. Relationship between platelet aggregating factor and von Willebrand factor in thrombotic thrombocytopenic purpura. Br J Haematol. 1987;66:509-513[Medline] [Order article via Infotrieve]. 19. Gerritsen H, Turecek P, Schwarz HP, Lammle BL, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999;82:1386-1389[Medline] [Order article via Infotrieve]. 20. Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP. Estimation of von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost. 1999;82:1382-1385[Medline] [Order article via Infotrieve]. 21. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393-397[Abstract].
22.
Burns ER, Zucker-Franklin D.
Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells.
Blood.
1982;60:1030-1037 23. Leung DY, Moake JL, Havens PL, Kim M, Pober JS. Lytic anti-endothelial antibodies in haemolytic-uraemic syndrome. Lancet. 1988;2:183-186[Medline] [Order article via Infotrieve]. 24. Lian EC, Siddiqui FA, Jamieson GA, Tandon NN. Platelet agglutinating protein p37 causes platelet activation through its binding to membrane glycoprotein IV. Thromb Haemost. 1991;65:102-106[Medline] [Order article via Infotrieve].
25.
Kelton JG, Moore JC, Murphy WG.
Studies investigating platelet aggregation and release initiated by sera from patients with thrombotic thrombocytopenic purpura.
Blood.
1987;69:924-928 26. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol. 1994;88:816-825[Medline] [Order article via Infotrieve]. 27. Schultz DR, Arnold PI, Jy W, et al. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura amd other thrombocytopenic disorders: identification of an 85-kD form of CD36 as a target antigen. Br J Haematol. 1998;103:849-857[CrossRef][Medline] [Order article via Infotrieve].
28.
Kelton JG, Warkentin TE, Hayward CPM, Murphy WG, Moore JC.
Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles.
Blood.
1992;80:2246-2251
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  B. Lammle, J. A. Kremer Hovinga, and J. N. George Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease Haematologica, February 1, 2008; 93(2): 172 - 177. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Song, K. A Lee, T. S. Park, R. Park, and J. R. Choi Linear Relationship between ADAMTS13 Activity and Platelet Dynamics Even Before Severe Thrombocytopenia Ann. Clin. Lab. Sci., January 1, 2008; 38(4): 368 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Mannucci Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: much progress and many remaining issues Haematologica, July 1, 2007; 92(7): 878 - 880. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Mannucci and F. Peyvandi TTP and ADAMTS13: When Is Testing Appropriate? Hematology, January 1, 2007; 2007(1): 121 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Levy, D. G. Motto, and D. Ginsburg ADAMTS13 turns 3 Blood, July 1, 2005; 106(1): 11 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Heemskerk, N. Scott-Douglas, S. Yilmaz, and K. McLaughlin Resolution of thrombotic microangiopathy following renal transplant Nephrol. Dial. Transplant., March 1, 2005; 20(3): 639 - 641. [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Linenberger and T. H. Price Use of Cellular and Plasma Apheresis in the Critically Ill Patient: Part II: Clinical Indications and Applications J Intensive Care Med, March 1, 2005; 20(2): 88 - 103. [Abstract] [PDF]
|
|
|
|
|
|
G. Wolf Not known from ADAM(TS-13)--novel insights into the pathophysiology of thrombotic microangiopathies Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1687 - 1693. [Full Text] [PDF]
|
|
|
|
|
|
S. K. Vesely, J. N. George, B. Lammle, J.-D. Studt, L. Alberio, M. A. El-Harake, and G. E. Raskob ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients Blood, July 1, 2003; 102(1): 60 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Savasan, S.-K. Lee, D. Ginsburg, and H.-M. Tsai ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity Blood, June 1, 2003; 101(11): 4449 - 4451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-M. Tsai Advances in the Pathogenesis, Diagnosis, and Treatment of Thrombotic Thrombocytopenic Purpura J. Am. Soc. Nephrol., April 1, 2003; 14(4): 1072 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-M. Tsai Platelet Activation and the Formation of the Platelet Plug: Deficiency of ADAMTS13 Causes Thrombotic Thrombocytopenic Purpura Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 388 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-M. Tsai, B. Lammle, V. Bianchi, L. Alberio, M. Furlan, G. Remuzzi, M. Galbusera, and P. M. Mannucci Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura Blood, November 15, 2002; 100(10): 3839 - 3842. [Full Text] [PDF]
|
|
|
|
 |
|
 J S Blake and L Butani Rapidly progressive lupus glomerulonephritis and concomitant microangiopathy in an adolescent Lupus, August 1, 2002; 11(8): 533 - 535. [Abstract] [PDF]
|
|
|
|
|
|
V. Bianchi, R. Robles, L. Alberio, M. Furlan, and B. Lammle Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura Blood, June 28, 2002; 100(2): 710 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Riemekasten, S Ziemer, T Haupl, C Melzer, K Loddenkemper, S Hauptmann, G R Burmester, and F Hiepe Shwartzman phenomenon in a patient with active systemic lupus erythematosus preceding fatal disseminated intravascular coagulation Lupus, April 1, 2002; 11(4): 204 - 207. [Abstract] [PDF]
|
|
|
|
|
|
J. N. George, J. E. Sadler, and B. Lammle Platelets: Thrombotic Thrombocytopenic Purpura Hematology, January 1, 2002; 2002(1): 315 - 334. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
those with reduced and those with normal vWF protease
activity